Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy

The effects of Riociguat, an oral soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension (CPAH). Respiratory status (n=8/10), right heart dilation (n=7/10), function (n=9/10) and CPAH (n=8/10) improved. Median decrement in systolic 12[4,14] diastolic 14[7,20] and mean arterial pressure 14[10,17] were noted; no critical hypotension or hypoxemia occurred.

source https://www.jpeds.com/article/S0022-3476(22)01079-4/fulltext?rss=yes

Comments

Popular posts from this blog

CLINICAL ROTATIONS VLOG #medicalschool #premed #vlog

Alumni Testimonials - Puerto Rico

What is OB-GYN? #obgyn #medicalspecialty #premed